Group 1 - The core viewpoint of the article highlights the growth potential of the autoimmune disease (AID) drug market, which is expected to reach $107.9 billion by 2024 and grow to $137.59 billion by 2033, driven by high clinical demand for conditions like atopic dermatitis and asthma [1] - The article notes that the global autoimmune sector is experiencing active large-scale business development (BD) transactions, with companies acquiring assets related to TL1A monoclonal antibodies and S1PR modulators [1] - In China, the overseas licensing of autoimmune drugs is significantly increasing, with transaction amounts projected to reach $3.108 billion in 2024, accounting for nearly one-third of recent total amounts [1] Group 2 - The vaccine ETF (159643) has risen over 2.3%, tracking the vaccine biotechnology index (980015), which focuses on companies involved in vaccine research, production, and sales [1] - The index comprises stocks from biotechnology firms with high market influence and technical strength, reflecting the overall performance and innovation dynamics in the vaccine and related biotechnology sectors [1]